First clinical assessment of [
Blood–Brain barrier
Dosimetry
First-in-human
P-glycoprotein
Positron emission tomography
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
25
05
2021
accepted:
02
08
2021
pubmed:
10
8
2021
medline:
29
1
2022
entrez:
9
8
2021
Statut:
ppublish
Résumé
5-(1-(2-[ [ No serious adverse events occurred throughout the study period. Although biodistribution implied hepatobiliary excretion, secretion of radioactivity from liver to small intestine through the gallbladder was very slow. Total renal excreted radioactivity recovered during 6 h after injection was < 2%ID. Absorbed dose was the highest in the pancreas (mean ± SD, 203 ± 45 μGy/MBq) followed by the liver (83 ± 11 μGy/MBq). Mean effective dose with and without urination was 17 ± 1 μSv/MBq. [ This initial evaluation indicated that [
Identifiants
pubmed: 34368924
doi: 10.1007/s12149-021-01666-9
pii: 10.1007/s12149-021-01666-9
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240-1252Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K07658
Organisme : Japan Society for the Promotion of Science
ID : 21K07663
Informations de copyright
© 2021. The Japanese Society of Nuclear Medicine.
Références
Terasaki T, Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology, and methodology. NeuroRx. 2005;2:63–72.
pmcid: 539321
doi: 10.1602/neurorx.2.1.63
pubmed: 15717058
Giacomini KM, Huang S-M. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94:3–9.
doi: 10.1038/clpt.2013.86
pubmed: 23778703
Graff CL, Pollack GM. Drug transporter at the blood–brain barrier and the choroid plexus. Curr Drug Metab. 2004;5:95–108.
doi: 10.2174/1389200043489126
pubmed: 14965253
Löscher W, Potschka H. Drug resistance in brain disease and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591–602.
doi: 10.1038/nrn1728
pubmed: 16025095
Feldmann M, Koepp M. ABC transporter and drug resistance in patients with epilepsy. Curr Pharm Des. 2016;22:5793–807.
doi: 10.2174/1381612822666160810150416
pubmed: 27514707
Ilyas-Feldmann M, Asselin M-C, Wang S, McMahon A, Anton-Rodriguez A, Brown G, et al. P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[
doi: 10.1111/epi.16581
pubmed: 32627849
Volk HA, Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain. 2005;128:1358–68.
doi: 10.1093/brain/awh437
pubmed: 15716304
O’Brien FE, Clarke G, Fitzgerald P, Dinan TG, Griffin BT, Cryan JF. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol. 2012;166:1333–43.
pmcid: 3417450
doi: 10.1111/j.1476-5381.2012.01858.x
pubmed: 22250926
de Klerk OL, Willemsen AT, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ, et al. Locally increased P-glycoprotein function in major depression: a PET study with [
doi: 10.1017/S1461145709009894
pubmed: 19224656
Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-protease inhibitors. J Clin Invest. 1998;101:289–94.
pmcid: 508566
doi: 10.1172/JCI1269
pubmed: 9435299
Chai AB, Leung GKF, Callaghan R, Gelissen IC. P-glycoprotein: a role in the export of amyloid-β in Alzheimer’s disease? FEBS J. 2020;287:612–25.
doi: 10.1111/febs.15148
pubmed: 31750987
Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, et al. Activity of p-glycoprotein, a β-amyloid transporter at the blood–brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med. 2014;55:1106–11.
doi: 10.2967/jnumed.113.130161
pubmed: 24842892
van Assema DME, Lubberink M, Bauer M, van der Filer WM, Schuit RC, Windhorst AD, et al. Blood–brain barrier P-glycoprotein function in Alzheimer’s disease. Brain. 2012;135:181–9.
doi: 10.1093/brain/awr298
pubmed: 22120145
Bartels AL, Willemsen ATM, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease PSP and MSA. J Neural Transm (Vienna). 2008;115:1001–9.
doi: 10.1007/s00702-008-0030-y
Vautier S, Fernandez C. ABCB1: the role in Parkinson’s disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol. 2009;5:1349–58.
doi: 10.1517/17425250903193079
pubmed: 19663741
Luurtsema G, Elsinga P, Dierckx R, Boellaard R, van Waarde A. PET tracers for imaging of ABC transporters at the blood–brain barrier: principles and strategies. Curr Pharm Des. 2016;22:5779–85.
doi: 10.2174/1381612822666160810123634
pubmed: 27568733
Raaphorst RM, Windhorst AD, Elsinga PH, Colabufo NA, Lammertsma AA, Luurtsema G. Radiopharmaceuticals for assessing ABC transporters at the blood–brain barrier. Clin Pharmacol Ther. 2015;97:362–71.
doi: 10.1002/cpt.73
pubmed: 25669763
Lubberink M. Kinetic models for measuring P-glycoprotein function at the blood-brain barrier with positron emission tomography. Curr Pharm Des. 2016;22:5786–92.
doi: 10.2174/1381612822666160804093852
pubmed: 27494063
Luurtsema G, Molthoff CFM, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJF. Evaluation of (R)-[
doi: 10.1016/j.nucmedbio.2004.06.007
pubmed: 15691665
Savolainen H, Windhorst AD, Elsinga PH, Cantore M, Colabufo NA, Willemsen AT, et al. Evaluation of [
doi: 10.1177/0271678X16654493
pubmed: 27354093
Savolainen H, Cantore M, Colabufo NA, Elsinga PH, Windhorst AD, Luurtsema G. Synthesis and preclinical evaluation of three novel fluorine-18 labeled radiopharmaceuticals for P-glycoprotein PET imaging at the blood–brain barrier. Mol Pharm. 2015;12:2265–75.
doi: 10.1021/mp5008103
pubmed: 26043236
García-Varela L, Arif WM, García DV, Kakiuchi T, Ohba H, Harada N, et al. Pharmacokinetic modeling of [
pmcid: 7482398
doi: 10.1021/acs.molpharmaceut.0c00514
pubmed: 32787277
García-Varela L, García DV, Aguiar P, Kakiuchi T, Ohba H, Harada N, et al. Head-to-head comparison of (R)-[
doi: 10.1007/s00259-021-05411-2
pmcid: 8566421
pubmed: 34117508
Toyohara J, Sakata M, Tago T, Colabufo NA, Luurtsema G. Automated synthesis, preclinical toxicity, and radiation dosimetry of [
pmcid: 7376787
doi: 10.1186/s13550-020-00674-6
pubmed: 32700099
Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of
doi: 10.1007/s00259-013-2512-x
pubmed: 23868334
Toyohara J, Sakata M, Oda K, Ishii K, Ito K, Hiura M, et al. Initial human PET studies of metabotropic glutamate receptor type 1 ligand
doi: 10.2967/jnumed.113.119891
pubmed: 23804329
Ito K, Sakata M, Oda K, Wagatsuma K, Toyohara J, Ishibashi K, et al. Comparison of dosimetry between PET/CT and PET alone using
doi: 10.1007/s13246-015-0419-5
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.
doi: 10.1016/j.ejmp.2017.09.124
pubmed: 29173917
Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.
pubmed: 15937315
ICRP. The 2007 recommendations of the international commission on radiological protection ICRP publication 103. Ann ICRP. 2007;37:1–332.
Toyohara J, Yamamoto H, Tago T. Searching for diagnostic properties of novel fluorine-18-labeled D-allose. Ann Nucl Med. 2019;33:855–65.
doi: 10.1007/s12149-019-01398-x
pubmed: 31471865
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time–activity measurement applied to [N-
doi: 10.1038/jcbfm.1990.127
pubmed: 2384545
Auvity S, Caillé F, Marie S, Wimberley C, Bauer M, Langer O, et al. P-Glycoprotein (ABCB1) inhibits the influx and increases the efflux of
doi: 10.2967/jnumed.118.210104
pubmed: 29748235
Tournier N, Bauer M, Picher V, Nics L, Klebermass E-M, Bamminger K, et al. Impact of P-glycoprotein function on the brain kinetics of the weak substrate
pmcid: 6604692
doi: 10.2967/jnumed.118.219972
pubmed: 30630940
Fusi F, Durante M, Gorelli B, Perrone MG, Colabufo NA, Saponara S. MC225, a novel probe for P-glycoprotein PET imaging at the blood–brain barrier: in vitro cardiovascular safety evaluation. J Cardiovasc Pharmacol. 2017;70:405–10.
doi: 10.1097/FJC.0000000000000536
pubmed: 28877068
Brzezińska E. Synthesis and pharmacological properties of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives. Acta Pol Pharm. 1996;53:365–71.
pubmed: 9415212
ICRP. Radiological protection in biomedical research. ICRP Publication 62. Ann ICRP. 1992;22:1–18.
RDRC Final Guidance: human research without an investigational new drug application. 2010 https://www.fda.gov/media/76286/download . (Accessed Aug 2010).
Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of P-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol. 2010;596:199–222.
doi: 10.1007/978-1-60761-416-6_10
pubmed: 19949926
Bartels A, Kortekaas R, Bart J, Willemsen ATM, de Klerk OL, de Vries JJ, et al. Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2009;30:1818–24.
doi: 10.1016/j.neurobiolaging.2008.02.002
pubmed: 18358568
Bauer M, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, et al. Age dependency of cerebral P-gp function measured with (R)-[
pmcid: 3689922
doi: 10.1007/s00228-009-0709-5
pubmed: 19655132
Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer’s disease: preliminary observations. Neurobiol Aging. 2015;36:2475–82.
doi: 10.1016/j.neurobiolaging.2015.05.020
pubmed: 26159621
Toornvliet R, van Berckel BNM, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, et al. Effect of age on functional P-glycoprotein in the blood–brain barrier measured by use of (R)-[
doi: 10.1016/j.clpt.2006.02.004
pubmed: 16765142
van Assema DME, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al. P-glycoprotein function at the blood–brain barrier: effects of age and gender. Mol Imaging Biol. 2012;14:771–6.
pmcid: 3492696
doi: 10.1007/s11307-012-0556-0
pubmed: 22476967
Kervezee L, Hartman R, van den Berg D-J, Shimizu S, Emoto-Yamamoto Y, Meijer JH, et al. Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain. AAPS J. 2014;16:1029–37.
pmcid: 4147055
doi: 10.1208/s12248-014-9625-4
pubmed: 24917180
Savolainen H, Meerlo P, Elsinga PH, Windhorst AD, Dierckx RAJO, Colabufo NA, et al. P-glycoprotein function in the rodent brain displays a daily rhythm, a quantitative in vivo PET study. AAPS J. 2016;18:1524–31.
doi: 10.1208/s12248-016-9973-3
pubmed: 27600138
Vendelbo J, Olesen RH, Lauridsen JK, Rungby J, Kleinman JE, Hyde TM, et al. Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians. Pharmacogenomics J. 2018;18:121–6.
doi: 10.1038/tpj.2016.74
pubmed: 27897267
Banks WA. The blood–brain barrier interface in diabetes mellitus: dysfunctions, mechanisms and approaches to treatment. Curr Pharm Des. 2020;26:1438–47.
doi: 10.2174/1381612826666200325110014
pubmed: 32209037
Strock SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, et al. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain Behav Immun. 2018;73:21–33.
doi: 10.1016/j.bbi.2018.07.017
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20:1422–49.
pmcid: 3913737
doi: 10.2174/13816128113199990463
pubmed: 23789948
Sita G, Hrelia P, Tarozzi A, Morroni F. P-glycoprotein (ABCB1) and oxidative stress: focus on Alzheimer’s disease. Oxid Med Cell Longev. 2017;2017:7905486.
pmcid: 5727796
doi: 10.1155/2017/7905486
pubmed: 29317984
Alasmari F, Ashby CR Jr, Hall FS, Sari Y, Tiwari AK. Modulation of the ATP-binding cassette B1 transporter by neuro-inflammatory cytokines: role in pathogenesis of Alzheimer’s disease. Front Pharmacol. 2018;9:658.
pmcid: 6020013
doi: 10.3389/fphar.2018.00658
pubmed: 29973883
Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathway in obesity, diabetes, and Alzheimer’s disease. Biochem Biophys Acta Mol Basis Dis. 2017;1863:1037–45.
doi: 10.1016/j.bbadis.2016.04.017
Goldwaser EL, Acharya NK, Sarkar A, Godsey G, Nagele RG. Breakdown of the cerebrovasculature and blood–brain barrier: a mechanistic link between diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis. 2016;54:445–56.
doi: 10.3233/JAD-160284
pubmed: 27497477
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–8.
pmcid: 16264
doi: 10.1073/pnas.97.7.3473
pubmed: 10716719
Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee Y-J, et al. Evaluation of in vivo P-glycoprotein function at the blood–brain barrier among MDR1 gene polymorphisms by using
pubmed: 16954549
Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther. 2005;78:182–90.
doi: 10.1016/j.clpt.2005.04.011
pubmed: 16084852
Mossel P, García-Varela L, Arif WM, van der Weijdan CWJ, Boersma HH, Willemsen ATM, et al. Evaluation of P-glycoprotein function at the blood–brain barrier using [
doi: 10.1007/s00259-021-05419-8
pmcid: 8484189
pubmed: 34089347
García-Varela L, Rodríguez-Pérez M, Custoida A, Moraga-Amaro R, Colabufo NA, Aguiar P, et al. In vivo induction of P-glycoprotein function can be measured with [
doi: 10.1021/acs.molpharmaceut.1c00302
pmcid: 8383301
pubmed: 34228458